Ribomic is set to initiate Phase III trials for umedaptanib pegol (RBM-007), an oligonucleotide aptamer targeting anti-fibroblast growth factor 2 to treat achondroplasia. The therapy shows advantages compared to existing competitors in this rare dwarfism indication. Business development leads indicated ongoing preparations to progress clinical development to support potential regulatory filings.